Human medicines European public assessment report (EPAR): Votrient, pazopanib, Carcinoma, Renal Cell, Date of authorisation: 14/06/2010, Revision: 22, Status: Authorised

Case Medical Research ◽

10.31525/cmr-22bdf50 ◽

2019 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Sutent, sunitinib, Gastrointestinal Stromal Tumors,Carcinoma, Renal Cell,Neuroendocrine Tumors, Date of authorisation: 19/07/2006, Revision: 36, Status: Authorised

Case Medical Research ◽

10.31525/cmr-8cd85e ◽

2019 ◽

Author(s):

Keyword(s):

Neuroendocrine Tumors ◽

Gastrointestinal Stromal Tumors ◽

Assessment Report ◽

Stromal Tumors ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Carcinoma, Renal Cell, Date of authorisation: 25/08/2016, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-6ac70b ◽

2019 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Inlyta, axitinib, Carcinoma, Renal Cell, Date of authorisation: 03/09/2012, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-bb17b5 ◽

2019 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 19/06/2015, Revision: 27, Status: Authorised

Case Medical Research ◽

10.31525/cmr-962c37 ◽

2019 ◽

Author(s):

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Hodgkin Disease ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Sutent, sunitinib, Gastrointestinal Stromal Tumors,Carcinoma, Renal Cell,Neuroendocrine Tumors, Date of authorisation: 19/07/2006, Revision: 36, Status: Authorised

Case Medical Research ◽

10.31525/cmr-8d794b ◽

2019 ◽

Author(s):

Keyword(s):

Neuroendocrine Tumors ◽

Gastrointestinal Stromal Tumors ◽

Assessment Report ◽

Stromal Tumors ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Fotivda, tivozanib hydrochloride monohydrate, Carcinoma, Renal Cell, Date of authorisation: 24/08/2017, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-cc9825 ◽

2019 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Hydrochloride Monohydrate ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Carcinoma, Non-Small-Cell Lung,Breast Neoplasms,Ovarian Neoplasms,Colorectal Neoplasms,Carcinoma, Renal Cell, Date of authorisation: 12/01/2005, Revision: 51, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1b3e44e ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Colorectal Neoplasms ◽

Ovarian Neoplasms ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Afinitor, everolimus, Carcinoma, Renal Cell,Breast Neoplasms,Pancreatic Neoplasms, Date of authorisation: 02/08/2009, Revision: 23, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996f4 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Pancreatic Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Inlyta, axitinib, Carcinoma, Renal Cell, Date of authorisation: 03/09/2012, Revision: 10, Status: Authorised

Case Medical Research ◽

10.31525/cmr-babd62 ◽

2019 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Nexavar, sorafenib, Carcinoma, Hepatocellular,Carcinoma, Renal Cell, Date of authorisation: 19/07/2006, Revision: 28, Status: Authorised

Case Medical Research ◽

10.31525/cmr-221f788 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatocellular Carcinoma ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell ◽

Carcinoma Hepatocellular

Download Full-text